posted
Endovasc Announces Completion of Liprostin Manufacturing for Phase IIIa Trial
2006-09-06 08:30 ET - News Release
HOUSTON -- (Business Wire) -- Sept. 6, 2006
ENDOVASC INC. (OTCBB:EVSC), today announced that PYRAMID Laboratories, Inc. has completed the cGMP manufacturing of Liprostin for the Company's proposed phase IIIa clinical trial for patients suffering from Intermittent Claudication. Endovasc's Liprostin is a liposome-encapsulated form of prostaglandin E-1 (PGE-1) which is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. In February 2006, Endovasc submitted its protocol for the phase IIIa clinical trial of Liprostin for treatment of intermittent claudication, a symptom of Peripheral Arterial Disease, to the FDA. Intermittent claudication causes a cramping sensation in the legs that is present during exercise or walking and occurs as a result of decreased blood and oxygen supply. If left untreated, clots may form and lead to leg ulcers, gangrene and ultimately amputation. "PYRAMID Laboratories is an excellent partner who has successfully manufactured Liprostin for us throughout the earlier phases of our FDA trials. We continue to focus our efforts on the selection of investigators and clinical sites," said Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer.
About PYRAMID Laboratories Inc.
PYRAMID Laboratories, Inc. is an independent professional service organization specializing in Contract Aseptic Manufacturing and Analytical Services for the pharmaceutical and biotechnology industries. PYRAMID's manufacturing services include formulation, processing, and aseptic filling capabilities for both vial and syringe as well as lyophilization applications. As an FDA registered Biopharmaceutical facility, PYRAMID is experienced in product development, formulation, manufacturing and supporting laboratory services compliant with GLP and cGMP guidelines. For more information, please visit www.pyramidlabs.com.
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing a stent coating technology; and Nutraceutical Development Corporation. For more information about Endovasc, please visit www.endovasc.com.
Safe Harbor:
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. Contacts:
Endovasc, Inc. Rob Johnson, 936-582-5920
Posts: 5120 | Registered: Jun 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
